Strong YoY growth masks Q1 sequential weakness; innovation pipeline credible but early-stage

16.6% YoY revenue growth but -5.7% QoQ; PAT flat YoY at 15.7% but -14.6% QoQ sequential decline severe

Shingrix 65% growth, oncology touched 260+ patients, Nucala 600 active patients. Real traction but still <10% of revenue base

Management explicitly disclosed 4-5pp benefit from prior-year CMO disruptions; underlying growth statement plausible

OPM 31.5%, NPM 24.1% reported; margin expansion intact but flat on sequential basis given QoQ PAT decline

No quantified Calpol recovery figures given. Claim hedged with 'worst is behind us' and underlying growth proof

7% of revenue vs 4% last year (₹69 Cr volume implied). Drove 4pp of growth. Shingrix scaled to ₹100+ Cr MAT; oncology entered non-trivial zone (263 patients Q1, contributing to overall top line).

FY26 guidance to double revenue to ₹8,000 Cr in 5-7 years (~12-14% CAGR) restated. No change, but path narrowing: sequential weakness suggests execution risk.

YoY EBITDA margins +50 bps, but QoQ PAT -14.6% signals margin pressure this quarter. CFO projects normalization to 34% EBITDA range vs current 31.5% OPM; imports of oncology drugs at lower margin mix.

36% YoY opex rise deliberate front-loading: 3,800 HCP events, international speaker meets ahead of Q2 peak season. Expect moderation in Q2–Q3. Shows aggressive go-to-market for innovation.

Gen Med still growing double-digit in India (rare globally). GSK has 60+ clinical trials entering India, reducing drug-to-market lag. Specialty aligns with India opportunity, not conflicts.

Worst behind us. Underlying growth 9-10% proof of recovery. Stress-tested supply chain; business continuity plans strengthened. No specific recovery figures given.

45,000–50,000 doses quarterly. 65% YoY growth. Crossed ₹100 Cr MAT. Demographic: 10–12 million 50+ Indian adults with comorbidities addressable.

600–700 patients in first 6 months; 250–300 quarterly. 40 people in oncology/hematology team already at productivity within 11 months. Zejula top 5 PARP inhibitors in fragmented market.

Marketing authorization approved. 7,000–8,000 eligible second-line patients annually. Launch in Q2 or Q3 FY27 latest. Team in place, training underway.

Deliberate front-loading Q1: 3,800 HCP events, international speakers ahead of Q2 peak. Expect moderation to historical trends in Q2–Q4. Phasing, not pulling.

Burden of disease 40 million. Hypothesis: cured patients = acute therapy; non-cured = chronic. Testing in India market. Details deferred to Q2 (too nascent to answer now).

Volume 3–3.5%, price 6%, new introductions (innovation) remainder. All three levers ticked.

No formal guidance given. Intent to sustain double-digit growth. Focus on innovative assets as arrowheads. Long-term vision intact.

~600 active patients currently (tripled from last year). Severe eosinophilic asthma patients 50–60 per month last year; doubled to 100–120 per month this year.

Implies 12–14% CAGR from ~₹4,000 Cr FY26 base (~₹938 Cr Q1 suggests full-year trajectory ~₹4,000–4,100 Cr). Current 16.6% YoY ahead, but underlying 9–10% after favorable base effect.

S&A ratios expected to normalize to historical levels. Margin expansion held despite front-loaded Q1 opex (+36% YoY).

Q1 QoQ revenue -5.7%, PAT -14.6% despite YoY growth. Suggests Q2 acute season must deliver to restore momentum. If Q2 also declines QoQ, 12–14% annual target at risk.

Belantamab (Blenrep, oncology), Arexvy (RSV vaccine), Bepirovirsen (hepatitis B) all launching in Q2–Q4 FY27. Still early-stage: Belantamab 263 patients total (pilot scale); Bepirovirsen market model undefined. Scaling & profitability unproven.

GSK global announced specialty-led restructuring, 60+ clinical trials entering India pipeline. Risk: India Gen Med (still 60% of portfolio) may see reduced investment if parent shifts capital to specialty globally. Management downplayed but structural risk exists.

Imported oncology/specialty drugs carry lower gross margins than locally-manufactured Gen Med. As innovation mix grows from 7% toward higher contribution, blended margin profile compresses. CFO projects EBITDA normalization to 34% range.

Bepirovirsen (Hibsago) functional cure for hepatitis B novel therapy. Commercialization pricing model unresolved: cured patients pay short-term (high clinical benefit, low durability pay), non-cured pay lifelong (low clinical benefit, high durability pay). Management deferred to Q2. Pricing risk high.